Cargando…
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
BACKGROUND: This phase 1 study examined the safety, maximum-tolerated dose (MTD) and antitumour activity of E7449, a novel PARP 1/2 and tankyrase 1/2 inhibitor. METHODS: E7449 was orally administered once daily in 28-day cycles to patients with advanced solid tumours (50–800-mg doses). Archival tumo...
Autores principales: | Plummer, Ruth, Dua, Divyanshu, Cresti, Nicola, Drew, Yvette, Stephens, Peter, Foegh, Marie, Knudsen, Steen, Sachdev, Pallavi, Mistry, Bipin M., Dixit, Vaishali, McGonigle, Sharon, Hall, Nancy, Matijevic, Mark, McGrath, Shannon, Sarker, Debashis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434893/ https://www.ncbi.nlm.nih.gov/pubmed/32523090 http://dx.doi.org/10.1038/s41416-020-0916-5 |
Ejemplares similares
-
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
por: McGonigle, Sharon, et al.
Publicado: (2015) -
The telomeric PARP, tankyrases, as targets for cancer therapy
por: Seimiya, H
Publicado: (2006) -
Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2
por: Qiu, Wei, et al.
Publicado: (2014) -
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
por: Ryan, Kevin, et al.
Publicado: (2021) -
Tankyrase 1 and Tankyrase 2 Are Essential but Redundant for Mouse Embryonic Development
por: Chiang, Y. Jeffrey, et al.
Publicado: (2008)